The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib-Reference-Cited by-同舟云学术

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

Published:2017-03 Issue:2 Volume:16 Page:263-268
ISSN:1665-2681
Container-title:Annals of Hepatology
language:en
Short-container-title:Annals of Hepatology

Author:

Branco Fernanda,Alencar Regiane S.M.,Volt Fernanda,Sartori Giovana,Dode Andressa,Kikuchi Luciana,Tani Claudia M.,Chagas Aline L.,Pfiffer Tulio,Hoff Paulo,Carrilho Flair J.,Alves de Mattos Angelo

Publisher

Elsevier BV

Subject

Hepatology,General Medicine

Link

https://publisherspanel.com/icid/pdf/1231587

Reference22 articles.

1. Risk factors of hepatocellular carcinoma--current status and perspectives;Gao;Asian Pac J Cancer Prev,2012

2. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study;Fassio;Ann Hepatol,2010

3. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil;Carrilho;Clinics (Sao Paulo),2010

4. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

5. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hy-poxia in RCC xenograft models;Chang;Cancer Chemother Pharmacol,2007

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials;Clinical Pharmacology & Therapeutics;2024-05-27

2. Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma;Cancers;2024-04-13

3. Large Volume Paracentesis in Patients with Liver Cirrhosis Temporarily Diminishes Blood Cell Count;IRAN J MED SCI;2023

4. Diagnostic and therapeutic abdominal paracentesis;Medical Journal of Australia;2022-11-30

5. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities;Cancers;2022-08-20